Healthcare Active Runners: Merck & Co. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE), Ariad Pharmaceuticals (NASDAQ:ARIA)

Merck & Co., Inc. (NYSE:MRK) is getting close to conducting phase 3 trials for a combination treatment for Hepatitis C, which could potentially rejuvenate the pharmaceutical giant’s revenue growth. The clinical data for a combination of drugs MK-5172 and MK-8742 has showed high cure rates among patients with genotype 1 of the disease, and this has encouraged Merck to move to phase 3 trials. Merck … Continue reading Healthcare Active Runners: Merck & Co. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE), Ariad Pharmaceuticals (NASDAQ:ARIA)

Healthcare Active Runners: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK)

Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Monday, May 5, 2014. Pfizer Inc. (NYSE:PFE) stock performance was 1.05% in last session and finished the day at $31.82. Traded volume was 21.09million shares in the last session and the average volume of the stock remained … Continue reading Healthcare Active Runners: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK)

US pharma giant Pfizer (NYSE:PFE) has announced detailed results from OPT Compare (A3921080), a Phase III study of tofacitinib (trade name Xeljanz), the first in a new class of treatment, oral Janus kinase (JAK) inhibitors, the safety and efficacy of which are being investigated for the treatment of adults with moderate-to-severe chronic plaque psoriasis. Pfizer Inc. (NYSE:PFE) stock performance was -2.14% in last session and … Continue reading Healthcare Active Stocks: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb (NYSE:BMY), Merck & Co (NYSE:MRK)

Arena Pharmaceuticals Inc (NASDAQ: ARNA ) and VIVUS (NASDAQ: VVUS ) in early 2012 as each company headed into their regulatory reviews with the U.S. Food and Drug Administration, or FDA, for their respective obesity medications. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock performance was -2.84% in last session and finished the day at $6.49. Traded volume was 6.83million shares in the last session and the average … Continue reading Active Stocks Healthcare: Arena Pharmaceuticals (NASDAQ:ARNA), Pfizer Inc. (NYSE:PFE), Merck & Co. (NYSE:MRK), Teva Pharmaceutical Industries (NYSE:TEVA)

Bristol-Myers Squibb Co (NYSE:BMY)’s ipilimumab, or Yervoy as it’s commercially known, was dubbed the skin cancer ‘wonder’ drug by the media when it was licensed for use in the UK in 2011. Bristol-Myers Squibb Co (NYSE:BMY) dropped -0.33 percent to $54.00 Friday on volume of 8.05million shares. The intra-day range of the stock was $53.88 to $54.44. Bristol-Myers Squibb Co (NYSE:BMY) has a market capitalization … Continue reading Drug manufacturer Most Active: Merck & Co. (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY), Johnson & Johnson (NYSE:JNJ), Raptor Pharmaceutical (NASDAQ:RPTP)

Shares of Peregrine Pharmaceuticals (NASDAQ: PPHM ) , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer, dipped as much as 11% after reporting its third-quarter earnings results. Peregrine Pharmaceuticals (NASDAQ:PPHM) stock performance was -8.05% in last session and finished the day at $2.40. Traded volume was 14.14million shares in the last session and the average volume of the stock remained 4.31million shares. … Continue reading Healthcare Active Stocks: Peregrine Pharmaceuticals (NASDAQ:PPHM), Merck & Co (NYSE:MRK), Teva Pharmaceutical Industries (NYSE:TEVA), Abbott Laboratories (NYSE:ABT)